{"prompt": "['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', '9.4.', 'Key Elements of Analysis Plan', '59', '9.4.1.', 'Primary Analyses', '59', '9.4.2.', 'Other Analyses', '60', '10. STUDY GOVERNANCE CONSIDERATIONS', '61', '10.1. Posting of Information on Publicly Available Clinical Trial Registers', '61', '10.2.', 'Regulatory and Ethical Considerations, Including the Informed', 'Consent Process', '61', '10.3. Quality Control (Study Monitoring)', '62', '10.4.', 'Quality Assurance', '62', '10.5.', 'Study and Site Closure', '62', '10.6.', 'Records Retention', '63', '10.7.', 'Provision of Study Results to Investigators, Posting of Information', 'on Publically Available Clinical Trials Registers and Publication', '64', '11. REFERENCES', '65', '12. APPENDICES', '68', '12.1. Appendix 1: Abbreviations and Trademarks', '68', '12.2.', 'Appendix 2: Liver Safety Required Actions and Follow up', 'Assessments', '70', '12.3.', 'Appendix 3: Genetic Research', '73', '12.4.', 'Appendix 4: Definition of and Procedures for Recording, Evaluating,', 'Follow-Up and Reporting of Adverse Events', '76', '12.4.1.', 'Definition of Adverse Events', '76', '12.4.2.', 'Definition of Serious Adverse Events', '77', '12.4.3.', 'Definition of Cardiovascular Events', '78', '12.4.4.', 'Recording of AEs and SAEs', '79', '12.4.5.', 'Evaluating AEs and SAEs', '79', '12.4.6.', 'Reporting of SAEs to GSK', '81', '12.5. Appendix 5: COPD Exacerbation Identification, Categorization and', 'Treatment Guidelines', '82', '12.5.1.', 'Guidelines for Identifying COPD Exacerbations', '82', '12.5.2.', 'COPD Exacerbation Severity', '83', '12.5.3.', 'Treatment of COPD Exacerbations', '83', '12.5.4.', 'Guidelines for Treatment with Corticosteroids', '83', '12.5.5.', 'Guidelines for Treatment with Antibiotics', '84', '12.5.6.', 'Onset and Resolution of COPD Exacerbations', '84', '12.5.7.', 'Guideline for assessing multiple mild exacerbations', '84', '12.5.8.', 'Guideline for assessing exacerbations that increase in', 'severity', '84', '12.6.', 'Appendix 6: Definition of and Procedures for Documenting Medical', 'Device Incidents', '85', '12.6.1. Definitions of a Medical Device Incident', '85', '12.6.2. Documenting Medical Device Incidents', '86', '12.7.', 'Appendix 7: Modified List of Highly Effective Methods for Avoiding', 'Pregnancy in FRP and Collection of Pregnancy Information', '87', '12.7.1. Modified List of Highly Effective Methods for Avoiding', 'Pregnancy in Females of Reproductive Potential (FRP)', '87', '12.7.2.', 'Collection of Pregnancy Information', '87', '12.8. Appendix 8: Country Specific Requirements', '89', '12.9.', 'Appendix 9: protocol changes', '90', '9']['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', '1.', 'PROTOCOL SYNOPSIS FOR STUDY 201749', 'Rationale', 'The primary purpose of this study is to demonstrate improvements in lung function in', 'subjects treated with Umeclidinium/Vilanterol (UMEC/VI) compared with Umeclidinium', '(UMEC) for 24 weeks. A further important aspect of the study is to evaluate the effect of', 'UMC/VI, UMEC, and salmeterol with respect to health-related quality of life (HRQoL),', 'measured through patient reported outcomes (PROs) questionnaires, and lung function.', 'Additional assessments to further evaluate other measures of chronic obstructive', 'pulmonary disease (COPD) efficacy and symptoms control will be performed.', 'Objective(s)/Endpoint(s)', 'Objectives', 'Enpoints', 'Primary', 'To compare the effect of UMEC/VI', 'Change from baseline in trough Forced', '(62.5/25 mcg once daily) with UMEC', 'Expiratory Volume in One Second', '(62.5 mcg once daily) on lung function', '(FEV1) at week 24', 'Secondary', 'To compare UMEC/VI (62.5/25 mcg', 'Change from baseline in self', 'once daily), UMEC (62.5 mcg once', 'administered computerised (SAC)', 'daily) with salmeterol (50 mcg twice', 'transient dyspnea index (TDI)', 'daily) on patient reported outcomes', '(PROs)', 'Percentage of TDI responders', 'according to SAC TDI score. A', 'responder is defined as a >1 unit', 'improvement in SAC TDI score', 'Assessment of respiratory daily', 'symptoms over 24 weeks using', 'Evaluating Respiratory Symptoms-', 'COPD (E-RS) and its subscales', '(breathlessness, cough and sputum and', 'chest symptoms)', 'Percentage of E-RS responders', 'according to E-RS score (defined as', 'reduction in E-RS score of >2 or >3.35', 'units) from baseline', \"Change from baseline in St George's\", 'Respiratory Questionnaire (SGRQ-C)', 'Percentage of responders according to', 'SGRQ-C total score (defined as a 4', 'point or greater reduction from', '10']\n\n###\n\n", "completion": "END"}